Mounjaro®
Starting from £179.99/mo
Start journey Learn moreFeeling nervous before your first Wegovy injection is completely normal. Most people who start semaglutide have never self-injected before, and the idea can feel bigger than the reality. Wegovy is a prescription-only medicine requiring clinical assessment before it can be issued, so your prescriber has already weighed whether it suits you before it arrives. That context matters when the nerves are loud.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Yes, and it comes up more than you might think. A question our prescribers hear most weeks is some version of: "I've had my pen for three days and I still haven't done it." Sitting with a new medicine, especially an injectable one, is different from swallowing a tablet. It asks something of you that feels unfamiliar.
What often helps is understanding that the hesitation is rarely about the injection itself. It's more commonly about uncertainty: what if I feel awful? What if I do it wrong? What if it doesn't work? Those are reasonable questions, not signs that you shouldn't be doing this. The semaglutide overview on our site covers the broader clinical picture if you want grounding in the evidence before you begin.
The pen itself is worth examining before injection day. Wegovy is supplied as an auto-injector: you hold it against your skin, press, and the mechanism does everything else. The needle retracts and locks automatically. You do not press a plunger, and you do not pull a cap that exposes a visible needle. Many people report that the physical reality of the injection is considerably less dramatic than the version they had imagined.
The honest answer is that the most common side effects are gastrointestinal: queasiness, loose stools, constipation, or a vague sense of fullness that can feel uncomfortable. Some people get none of these. Some get all of them for a week and then little after that. The NHS medicines page for semaglutide sets out the full list clearly and is worth reading before you start.
The titration schedule exists partly to manage this. The 0.25mg starting dose is low enough that your body can adjust before the dose rises. Each step up follows the same principle. If side effects feel unmanageable at any point, that is a conversation to have with your prescriber rather than a reason to push through silently or stop without guidance.
One practical note on timing: some people find injecting in the evening, when they can rest if they feel off, easier than a morning dose, though the right day and time for Wegovy is ultimately a personal and clinical choice. Eating lightly, staying well hydrated and avoiding fatty meals in the first few days after each new dose can all reduce GI discomfort meaningfully.
The patient information leaflet that comes with your pen walks through each step with diagrams, and it should be your primary reference. The main things people worry about are picking the wrong injection site, not getting the full dose, or injecting incorrectly. In practice, the pen is hard to misuse: it locks before releasing the dose if you haven't pressed it firmly enough against the skin, and it shows a dose indicator once the injection is complete.
Injection sites are the outer thigh, abdomen (avoiding the area immediately around the navel), or upper arm. Rotating between sites each week reduces skin irritation. Cleaning the site with an alcohol swab beforehand is good practice. Getting the most from each weekly dose means the pen should come from the fridge, but unlike some other injectables it can be left at room temperature briefly before use, so check your leaflet for the exact window rather than relying on memory.
If you are starting through a regulated service, ongoing clinical aftercare means you have somewhere to direct specific questions about technique. You are not expected to work through procedural uncertainty alone.
Read the leaflet. Watch your prescribing service's guidance video if one exists. Look at Novo Nordisk's own patient resources on wegovy.co.uk, which include step-by-step injection guidance designed for first-timers. Then, if you still have specific clinical questions (about an existing health condition, a medicine you take, something in your history that concerns you) contact your prescriber directly before opening the pen.
Cost is sometimes a source of anxiety layered on top of the clinical nerves. If you haven't already looked at how Wegovy pricing works in the UK private market, that context can help you feel more settled about the decision as a whole. Knowing exactly what is included in what you've paid, and what ongoing support looks like, removes one variable from an already busy head.
The broader Wegovy treatment guide covers eligibility, the clinical rationale, and what the evidence shows over time, worth reading if you want the full picture before committing. And if you haven't yet had a consultation, starting a free clinical consultation is the right first step rather than a decision made alone.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.